ygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment  NCT04273529/Not yet recruiting, Feb20‐Jun30 2020
The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19  Placebo, drug: thalidomide  COVID‐19 thalidomide  40, all, 18 years and older  Treatment  Placebo comparator: control group α‐interferon: n